Hepatitis C Virus

More than 4 million people in the U.S. live with a hepatitis C virus (HCV) diagnosis. However, as of 2022, fewer than one-third of individuals infected with HCV have been cured due to barriers related to high direct-acting antiviral (DAA) pricing and the steps involved in determining someone’s degree of liver disease or fibrosis. In […]

Over the last two decades, injection opioid use has increased among reproductive-aged women, with resultant increases in mother-to-child hepatitis C virus (HCV) transmissions in the U.S. Direct-acting antiviral (DAA) treatment is highly effective at reducing and eliminating the risk of HCV transmissions. Yet, studies show lower odds of receiving DAA treatment for women compared to […]

CHERISH is excited to welcome a new pilot grant cohort for the 10th year. Spearheaded by CHERISH Pilot Grant Program Director Brandon Aden, the program is designed to help researchers gain familiarity with health economic evaluations, apply related methodologies to their pilot research, and build out the next stage of their careers. This year, CHERISH […]

Direct-acting antivirals (DAAs) have been available since 2015 for hepatitis C (HCV). Nonetheless, very few patients with HCV initiate DAA treatment, ranging from 5% to 30%. The location where a patient is first diagnosed can also influence the care patients receive afterward, especially when a referral to a specialist or coordinated care is needed. In […]

Children with perinatally acquired hepatitis C virus (HCV) are now eligible to receive direct-acting antivirals (DAAs), a highly effective treatment for HCV, as early as the age of 3. Despite existing studies demonstrating DAA’s high efficacy and tolerance among adults and children between the 3 and 12 years old, there has been low uptake due […]